CMTM4 and neoplasm: However, CMTM4 KO cells show elevated sensitivity to gefitinib treatment (Fig. 5B; Appendix Fig. S7B,C), indicating CMTM4 plays a role in tumor intrinsic resistance to EGFR tyrosine kinase inhibitors.